The scan is increasingly used in clinical trials to exclude patients without evidence of dopamine deficiency who are unlikely to have the pathology that typically causes PD.6 There are limited data on the sensitivity of DAT binding to longitudinal change, which is an essential question if DAT imaging is to be used as an imaging biomarker in PD clinical trials. Here, SLC6A3 is linked to Parkinson disease.